Tirzepatide (tirzepatide) is a novel glucagon-like peptide-1 receptor (GLP-1) and glucose-dependent insulin-stimulating polypeptide (GIP, also known as gastric inhibitory polypeptide) double-receptor agonist administered once a week. Both GLP-1 and GIP belong to incretin, which is a Chemicalbook polypeptide secreted by the gastrointestinal mucosa. The former can bind to the receptors on the islet cells and stimulate insulin secretion, thus producing hypoglycemic effect, delaying gastric emptying and suppressing appetite, thus controlling body weight. The latter has the function of inhibiting gastric acid, pepsin secretion, stimulating insulin release, inhibiting gastric peristalsis and emptying, and can supplement the effect of GLP-1 receptor agonist.

Retatrutide is an investigational single molecule that activates the body's receptors for three hormones - glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), and is being studied for the treatment of obesity.
It employs a triple-agonist (triple-G) mechanism of action. In addition to being a GLP-1RA, it also targets gastric inhibitory polypeptide receptor (GIPR), and glucagon receptor (GCGR). This has consequently shown increased efficacy benefits in clinical trials, superior to those seen with W, which facilitates around -15% body weight loss.

Applications:

• 1.Treatment of depression and anxiety disorders: Retatrutide has been shown to have antidepressant and anxiolytic effects in preclinical studies, suggesting that it could be a promising treatment option for individuals with these conditions.
  2.Prevention of neurodegenerative diseases: Retatrutide has neuroprotective properties that may be useful in preventing or slowing the progression of neurodegenerative diseases such as Alzheimer's and Parkinson's.
  3.Enhancement of cognitive function: Retatrutide has been shown to improve learning and memory in animal studies, suggesting that it could have potential as a cognitive enhancer in humans.
  4.Treatment of chronic pain: Retatrutide has been shown to have analgesic effects in preclinical studies, suggesting that it could be a useful treatment option for individuals with chronic pain conditions.
  5.Promotion of wound healing: Retatrutide has been shown to accelerate wound healing in animal studies, suggesting that it could have potential as a therapeutic agent for promoting wound healing in humans.

CERTIFICATE  OF  ANALYSIS
Product name:  Retatrutide
CAS: 910463-68-2

Shaanxi TNJONE Pharmaceutical Co., Ltd is a high-tech enterprise mainly engaged inthe development and sale of pharmaceutical chemical raw materials and relatedproducts.The company has advanced and perfect supporting system,forming advancedchemical synthesis technology, which can quickly meet the individual needs and serialdevelopment from suitable detection to industrial production.Qur business covers morethan 30 countries, most of customers from Europe, Southeast Asia and other countriesin the world, we can guarantee the quality and price. Our enterprise purpose is basedon the market, strengthen strength, take the road of scientific environmental protectionand sustainable development, rely on the country. The company has a strong financialstrength and a good business environment, can provide customers with quality,efficientand fast service.